Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Schema
  9. External Links
  10. Analytics And Tracking
  11. Libraries
  12. CDN Services

We are analyzing https://link.springer.com/article/10.1007/s10557-016-6675-0.

Title:
Reduction of Atherosclerotic Lesions by the Chemotherapeutic Agent Carmustine Associated to Lipid Nanoparticles | Cardiovascular Drugs and Therapy
Description:
After injection in the bloodstream, a lipid nanoparticle (LDE) resembling low-density lipoprotein (LDL) concentrates in atherosclerotic lesions of cholesterol-fed rabbits. Here, rabbits with atherosclerosis were treated with carmustine, an antiproliferative agent used in cancer chemotherapy, associated to LDE to investigate the effects on the lesions. Twenty-seven male New Zealand rabbits were fed a 1 % cholesterol diet for 8 weeks. After 4 weeks nine animals were treated with intravenous saline solution, nine with intravenous LDE alone, and nine with intravenous LDE-carmustine (4 mg/kg, weekly for 4 weeks). LDE-carmustine reduced lesion size by 90 % compared to the controls. LDE-carmustine reduced the presence of macrophages, vascular smooth muscle cells, and regulatory T cells in the arterial intima, as well as the presence of matrix metallopeptidase-9, interleukin-1β and TNF-α and lipoprotein receptors, namely LDL-receptor, LDL-related protein-1, scavenger receptor class B member 1. When injected alone, without association to carmustine, LDE was not different from injected saline solution. LDE-carmustine treatment resulted in marked reduction of lesion area, of the invasion of the arterial intima by macrophages and vascular smooth muscle cells and pro-inflammatory factors. Therefore, this new formulation shows great potential for therapy of atherosclerotic cardiovascular disease.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

  • Health & Fitness
  • Education
  • Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We find it hard to spot revenue streams.

Many websites are intended to earn money, but some serve to share ideas or build connections. Websites exist for all kinds of purposes. This might be one of them. Link.springer.com might be earning cash quietly, but we haven't detected the monetization method.

Keywords {🔍}

pubmed, article, google, scholar, cas, maranhão, atherosclerosis, atherosclerotic, lipid, lde, rabbits, cells, cancer, cholesterolrich, lipoprotein, treatment, central, pharmacol, disease, cardiovascular, reduction, lesions, carmustine, lowdensity, heart, med, patients, microemulsion, privacy, cookies, content, bulgarelli, raul, ldl, cholesterol, receptors, access, study, etoposide, plasma, nanoemulsion, rodrigues, data, publish, research, search, drugs, therapy, daminelli, resembling,

Topics {✒️}

month download article/chapter cholesterol drug-targeting access resembling low-density lipoprotein related subjects low-density lipoprotein receptors ldl-related protein-1 cholesterol-fed rabbits article cardiovascular drugs full article pdf de vries aj low-density lipoprotein cholesterol-rich nanoemulsions murine primary cholesterol-rich emulsion privacy choices/manage cookies research career award low-density lipoproteins cholesterol-rich microemulsion technological development defective inflammation resolution intravenous saline solution high-density lipoproteins anti-inflammatory therapeutics cholesterol-rich nanoemulsion human atherosclerotic lesions mature whhl rabbits cardiovasc drugs ther acute coronary syndromes hyperlipidemic subjects major precursor lesion atherosclerotic cardiovascular disease acute myeloid-leukemia recurrent cardiovascular events trends mol med lo prete ac intravenous lde-carmustine lde-carmustine reduced invasive drug delivery pro-inflammatory factors oxldl-induced s100a12 espinosa-luna je legorreta-haquet mv preventing ischemic events radiation-induced atheromatosis thin-cap fibroatheroma curr opin cardiol tcrαβ chains associate curr atheroscler rep short-term administration medical school hospital

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Reduction of Atherosclerotic Lesions by the Chemotherapeutic Agent Carmustine Associated to Lipid Nanoparticles
         description:After injection in the bloodstream, a lipid nanoparticle (LDE) resembling low-density lipoprotein (LDL) concentrates in atherosclerotic lesions of cholesterol-fed rabbits. Here, rabbits with atherosclerosis were treated with carmustine, an antiproliferative agent used in cancer chemotherapy, associated to LDE to investigate the effects on the lesions. Twenty-seven male New Zealand rabbits were fed a 1 % cholesterol diet for 8 weeks. After 4 weeks nine animals were treated with intravenous saline solution, nine with intravenous LDE alone, and nine with intravenous LDE-carmustine (4 mg/kg, weekly for 4 weeks). LDE-carmustine reduced lesion size by 90 % compared to the controls. LDE-carmustine reduced the presence of macrophages, vascular smooth muscle cells, and regulatory T cells in the arterial intima, as well as the presence of matrix metallopeptidase-9, interleukin-1β and TNF-α and lipoprotein receptors, namely LDL-receptor, LDL-related protein-1, scavenger receptor class B member 1. When injected alone, without association to carmustine, LDE was not different from injected saline solution. LDE-carmustine treatment resulted in marked reduction of lesion area, of the invasion of the arterial intima by macrophages and vascular smooth muscle cells and pro-inflammatory factors. Therefore, this new formulation shows great potential for therapy of atherosclerotic cardiovascular disease.
         datePublished:2016-09-15T00:00:00Z
         dateModified:2016-09-15T00:00:00Z
         pageStart:433
         pageEnd:443
         sameAs:https://doi.org/10.1007/s10557-016-6675-0
         keywords:
            Atherosclerosis treatment
            Nanoparticles
            Solid lipid particles (SLP)
            Cholesterol
            Drug-targeting
            Cardiology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10557-016-6675-0/MediaObjects/10557_2016_6675_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10557-016-6675-0/MediaObjects/10557_2016_6675_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10557-016-6675-0/MediaObjects/10557_2016_6675_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10557-016-6675-0/MediaObjects/10557_2016_6675_Fig4_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10557-016-6675-0/MediaObjects/10557_2016_6675_Fig5_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10557-016-6675-0/MediaObjects/10557_2016_6675_Fig6_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10557-016-6675-0/MediaObjects/10557_2016_6675_Fig7_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10557-016-6675-0/MediaObjects/10557_2016_6675_Fig8_HTML.gif
         isPartOf:
            name:Cardiovascular Drugs and Therapy
            issn:
               1573-7241
               0920-3206
            volumeNumber:30
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Elaine N. Daminelli
               affiliation:
                     name:University of São Paulo
                     address:
                        name:Heart Institute of the Medical School Hospital, University of São Paulo, São Paulo, Brazil
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ana E. M. Martinelli
               affiliation:
                     name:University of São Paulo
                     address:
                        name:Heart Institute of the Medical School Hospital, University of São Paulo, São Paulo, Brazil
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Adriana Bulgarelli
               affiliation:
                     name:University of São Paulo
                     address:
                        name:Heart Institute of the Medical School Hospital, University of São Paulo, São Paulo, Brazil
                        type:PostalAddress
                     type:Organization
                     name:University of São Paulo
                     address:
                        name:Faculty of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Fatima R. Freitas
               affiliation:
                     name:University of São Paulo
                     address:
                        name:Heart Institute of the Medical School Hospital, University of São Paulo, São Paulo, Brazil
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Raul C. Maranhão
               affiliation:
                     name:University of São Paulo
                     address:
                        name:Heart Institute of the Medical School Hospital, University of São Paulo, São Paulo, Brazil
                        type:PostalAddress
                     type:Organization
                     name:University of São Paulo
                     address:
                        name:Faculty of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Reduction of Atherosclerotic Lesions by the Chemotherapeutic Agent Carmustine Associated to Lipid Nanoparticles
      description:After injection in the bloodstream, a lipid nanoparticle (LDE) resembling low-density lipoprotein (LDL) concentrates in atherosclerotic lesions of cholesterol-fed rabbits. Here, rabbits with atherosclerosis were treated with carmustine, an antiproliferative agent used in cancer chemotherapy, associated to LDE to investigate the effects on the lesions. Twenty-seven male New Zealand rabbits were fed a 1 % cholesterol diet for 8 weeks. After 4 weeks nine animals were treated with intravenous saline solution, nine with intravenous LDE alone, and nine with intravenous LDE-carmustine (4 mg/kg, weekly for 4 weeks). LDE-carmustine reduced lesion size by 90 % compared to the controls. LDE-carmustine reduced the presence of macrophages, vascular smooth muscle cells, and regulatory T cells in the arterial intima, as well as the presence of matrix metallopeptidase-9, interleukin-1β and TNF-α and lipoprotein receptors, namely LDL-receptor, LDL-related protein-1, scavenger receptor class B member 1. When injected alone, without association to carmustine, LDE was not different from injected saline solution. LDE-carmustine treatment resulted in marked reduction of lesion area, of the invasion of the arterial intima by macrophages and vascular smooth muscle cells and pro-inflammatory factors. Therefore, this new formulation shows great potential for therapy of atherosclerotic cardiovascular disease.
      datePublished:2016-09-15T00:00:00Z
      dateModified:2016-09-15T00:00:00Z
      pageStart:433
      pageEnd:443
      sameAs:https://doi.org/10.1007/s10557-016-6675-0
      keywords:
         Atherosclerosis treatment
         Nanoparticles
         Solid lipid particles (SLP)
         Cholesterol
         Drug-targeting
         Cardiology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10557-016-6675-0/MediaObjects/10557_2016_6675_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10557-016-6675-0/MediaObjects/10557_2016_6675_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10557-016-6675-0/MediaObjects/10557_2016_6675_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10557-016-6675-0/MediaObjects/10557_2016_6675_Fig4_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10557-016-6675-0/MediaObjects/10557_2016_6675_Fig5_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10557-016-6675-0/MediaObjects/10557_2016_6675_Fig6_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10557-016-6675-0/MediaObjects/10557_2016_6675_Fig7_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10557-016-6675-0/MediaObjects/10557_2016_6675_Fig8_HTML.gif
      isPartOf:
         name:Cardiovascular Drugs and Therapy
         issn:
            1573-7241
            0920-3206
         volumeNumber:30
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Elaine N. Daminelli
            affiliation:
                  name:University of São Paulo
                  address:
                     name:Heart Institute of the Medical School Hospital, University of São Paulo, São Paulo, Brazil
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ana E. M. Martinelli
            affiliation:
                  name:University of São Paulo
                  address:
                     name:Heart Institute of the Medical School Hospital, University of São Paulo, São Paulo, Brazil
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Adriana Bulgarelli
            affiliation:
                  name:University of São Paulo
                  address:
                     name:Heart Institute of the Medical School Hospital, University of São Paulo, São Paulo, Brazil
                     type:PostalAddress
                  type:Organization
                  name:University of São Paulo
                  address:
                     name:Faculty of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Fatima R. Freitas
            affiliation:
                  name:University of São Paulo
                  address:
                     name:Heart Institute of the Medical School Hospital, University of São Paulo, São Paulo, Brazil
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Raul C. Maranhão
            affiliation:
                  name:University of São Paulo
                  address:
                     name:Heart Institute of the Medical School Hospital, University of São Paulo, São Paulo, Brazil
                     type:PostalAddress
                  type:Organization
                  name:University of São Paulo
                  address:
                     name:Faculty of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cardiovascular Drugs and Therapy
      issn:
         1573-7241
         0920-3206
      volumeNumber:30
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of São Paulo
      address:
         name:Heart Institute of the Medical School Hospital, University of São Paulo, São Paulo, Brazil
         type:PostalAddress
      name:University of São Paulo
      address:
         name:Heart Institute of the Medical School Hospital, University of São Paulo, São Paulo, Brazil
         type:PostalAddress
      name:University of São Paulo
      address:
         name:Heart Institute of the Medical School Hospital, University of São Paulo, São Paulo, Brazil
         type:PostalAddress
      name:University of São Paulo
      address:
         name:Faculty of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil
         type:PostalAddress
      name:University of São Paulo
      address:
         name:Heart Institute of the Medical School Hospital, University of São Paulo, São Paulo, Brazil
         type:PostalAddress
      name:University of São Paulo
      address:
         name:Heart Institute of the Medical School Hospital, University of São Paulo, São Paulo, Brazil
         type:PostalAddress
      name:University of São Paulo
      address:
         name:Faculty of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Elaine N. Daminelli
      affiliation:
            name:University of São Paulo
            address:
               name:Heart Institute of the Medical School Hospital, University of São Paulo, São Paulo, Brazil
               type:PostalAddress
            type:Organization
      name:Ana E. M. Martinelli
      affiliation:
            name:University of São Paulo
            address:
               name:Heart Institute of the Medical School Hospital, University of São Paulo, São Paulo, Brazil
               type:PostalAddress
            type:Organization
      name:Adriana Bulgarelli
      affiliation:
            name:University of São Paulo
            address:
               name:Heart Institute of the Medical School Hospital, University of São Paulo, São Paulo, Brazil
               type:PostalAddress
            type:Organization
            name:University of São Paulo
            address:
               name:Faculty of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil
               type:PostalAddress
            type:Organization
      name:Fatima R. Freitas
      affiliation:
            name:University of São Paulo
            address:
               name:Heart Institute of the Medical School Hospital, University of São Paulo, São Paulo, Brazil
               type:PostalAddress
            type:Organization
      name:Raul C. Maranhão
      affiliation:
            name:University of São Paulo
            address:
               name:Heart Institute of the Medical School Hospital, University of São Paulo, São Paulo, Brazil
               type:PostalAddress
            type:Organization
            name:University of São Paulo
            address:
               name:Faculty of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Heart Institute of the Medical School Hospital, University of São Paulo, São Paulo, Brazil
      name:Heart Institute of the Medical School Hospital, University of São Paulo, São Paulo, Brazil
      name:Heart Institute of the Medical School Hospital, University of São Paulo, São Paulo, Brazil
      name:Faculty of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil
      name:Heart Institute of the Medical School Hospital, University of São Paulo, São Paulo, Brazil
      name:Heart Institute of the Medical School Hospital, University of São Paulo, São Paulo, Brazil
      name:Faculty of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(158)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Clipboard.js
  • Particles.js
  • Prism.js

CDN Services {📦}

  • Crossref

4.15s.